Home / Health / New Vaccine Fights Deadly Pancreatic Cancer
New Vaccine Fights Deadly Pancreatic Cancer
6 May
Summary
- Experimental mRNA vaccine custom-built for individual patients.
- Nearly 90% survival in patients with immune response up to six years.
- Personalized approach trains immune system to target cancer cells.
Pancreatic cancer, notoriously deadly with low survival rates, is now being targeted by an innovative, individualized mRNA vaccine. Researchers at Memorial Sloan Kettering (MSK) Cancer Center have developed this experimental therapy. Initial phase 1 clinical trial follow-up data reveals that nearly 90% of participants who exhibited an immune response to the vaccine remained alive up to six years post-treatment.
This personalized immunotherapy approach works by identifying unique proteins on a patient's cancer cells, called neoantigens. Scientists then create an mRNA vaccine instructing the patient's immune system to recognize and attack these specific markers. This "training tool" helps the immune system, particularly T-cells, to seek out and destroy cancer cells effectively.
While the findings are highly promising, experts caution that these are early results from a small patient group. Further research is ongoing to confirm the durability of these responses and explore optimal combinations with existing treatments. Challenges regarding cost, accessibility, and scalability must also be addressed for wider rollout.
